- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acromegaly;Functional carcinoid tumour;Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET).
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 499KB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 90KB)
Lanreotide – November 2022
Lanreotide: Injection 60 mg (as acetate) in single dose pre-filled syringe, Injection 90 mg (as acetate) in single dose pre-filled syringe, Injection 120 mg (as acetate) in single dose pre-filled syringe; Mytolac®
Last updated
3 March 2023